title: 3'-Fluoro substitution in the pyridine ring of epibatidine improves selectivity and efficacy for alpha4beta2 versus alpha3beta4 nAChRs.
abstract: The analog of epibatidine having a fluoro substituent at the 3' position of the pyridine ring has been recently developed and shown to possess binding affinity in the pM range to alpha4beta2 nAChRs and in the nM range to alpha7 nAChRs and to exhibit potent agonist activity in nicotine-induced analgesia tests. Here we used patch-clamp technique in a whole-cell configuration to compare functional activity of 3'-fluoroepibatidine to that of epibatidine by itself on recombinant alpha4beta2, alpha7 and alpha3beta4 neuronal nAChRs. The agonist effect of (+/-)-epibatidine was partial and yielded comparable EC50s of 0.012 microM (72% efficacy) and 0.027 microM (81% efficacy) at alpha4beta2 and alpha3beta4 nAChRs, respectively, but was full at alpha7 nAChRs with an EC50 of 4.8 muM. Testing of the analog at different concentrations revealed that it acts as a full agonist with an EC50 of 0.36 microM at alpha4beta2 nAChRs and induces partial agonist effect (66% efficacy) at alpha7 nAChRs with an EC50 of 9.8 microM and an IC50 corresponding to 225 microM. In contrast, the analog caused only 24% maximal activation at the range of concentrations from 0.1 to 100 microM and, in addition, induced an inhibition of alpha3beta4 nAChR function with an IC50 of 8.3 microM. Our functional data, which are in agreement with previous binding and behavioral findings, demonstrate that 3'-fluoro substitution in the pyridine ring of epibatidine results in an improved pharmacological profile as observed by an increased efficacy and selectivity for alpha4beta2 versus alpha3beta4 nAChRs.
authors.affiliation: Department of Pharmacology and Toxicology (G.R.A., M.I.D., B.R.M.), Virginia Commonwealth University, Richmond, VA 23298, United States. gabdrakhmano@vcu.edu
authors.forename: Galya R
authors.initials: GR
authors.lastname: Abdrakhmanova
authors.forename: F Ivy
authors.initials: FI
authors.lastname: Carroll
authors.forename: M I
authors.initials: MI
authors.lastname: Damaj
authors.forename: Billy R
authors.initials: BR
authors.lastname: Martin
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000737:chemistry* / Q000494:pharmacology; D002461:Cell Line, Transformed; D004079:Dihydro-beta-Erythroidine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008564:Membrane Potentials / Q000187:drug effects / Q000235:genetics; D018722:Nicotinic Agonists / Q000737:chemistry* / Q000494:pharmacology; D018408:Patch-Clamp Techniques / Q000379:methods; D011725:Pyridines / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000378:metabolism*; D013329:Structure-Activity Relationship; D014162:Transfection
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D018722:Nicotinic Agonists; D011725:Pyridines; D011978:Receptors, Nicotinic; C403530:nicotinic receptor alpha3beta4; C403531:nicotinic receptor alpha4beta2; D004079:Dihydro-beta-Erythroidine; C082748:epibatidine; D000109:Acetylcholine; C023666:pyridine
references.citation: Acta Pharmacol Sin. 2008 Mar;29(3):305-19
references.pmid: 18298895
references.citation: Mol Pharmacol. 2006 Aug;70(2):755-68
references.pmid: 16720757
references.citation: Annu Rev Pharmacol Toxicol. 2007;47:699-729
references.pmid: 17009926
references.citation: Neuroscience. 2002;109(4):757-65
references.pmid: 11927157
references.citation: J Neurosci. 1996 Dec 15;16(24):7892-901
references.pmid: 8987817
references.citation: Bioorg Med Chem Lett. 2004 Apr 19;14(8):1889-96
references.pmid: 15050621
references.citation: Proc West Pharmacol Soc. 1995;38:127-30
references.pmid: 7480004
references.citation: J Neurophysiol. 2007 Dec;98(6):3388-96
references.pmid: 17942622
references.citation: Neuropharmacology. 1999 Jun;38(6):769-83
references.pmid: 10465681
references.citation: Trends Pharmacol Sci. 2006 Sep;27(9):482-91
references.pmid: 16876883
references.citation: Recept Channels. 2001;7(6):491-6
references.pmid: 11918351
references.citation: Mol Pharmacol. 2005 Dec;68(6):1669-77
references.pmid: 16129734
references.citation: Nat Prod Rep. 2000 Apr;17(2):131-5
references.pmid: 10821107
references.citation: Mol Pharmacol. 2001 Sep;60(3):568-76
references.pmid: 11502889
references.citation: J Neurobiol. 2002 Dec;53(4):568-79
references.pmid: 12436421
references.citation: J Neurosci. 2003 Apr 15;23(8):3176-85
references.pmid: 12716925
references.citation: Mol Pharmacol. 1998 Aug;54(2):322-33
references.pmid: 9687574
references.citation: Neuropharmacology. 2000 Oct;39(13):2561-9
references.pmid: 11044727
references.citation: J Biol Chem. 2004 Sep 3;279(36):37842-51
references.pmid: 15234980
references.citation: Mol Pharmacol. 2003 Mar;63(3):574-80
references.pmid: 12606764
references.citation: Bioorg Med Chem Lett. 2005 Oct 1;15(19):4385-8
references.pmid: 16039849
references.citation: Nature. 1999 Apr 29;398(6730):805-10
references.pmid: 10235262
references.citation: Mol Pharmacol. 1999 Jun;55(6):970-81
references.pmid: 10347237
references.citation: Mol Pharmacol. 2008 Aug;74(2):348-59
references.pmid: 18445710
references.citation: J Mol Neurosci. 2006;30(1-2):15-6
references.pmid: 17192608
references.citation: Mol Pharmacol. 1992 Jan;41(1):31-7
references.pmid: 1732720
references.citation: Proc Natl Acad Sci U S A. 1987 Jan;84(2):595-9
references.pmid: 3467376
references.citation: Chem Biol. 2000 Jul;7(7):545-55
references.pmid: 10903939
references.citation: Behav Brain Res. 2000 Aug;113(1-2):131-41
references.pmid: 10942040
references.citation: Curr Pharm Des. 2006;12(4):407-28
references.pmid: 16472136
references.citation: Mol Pharmacol. 2006 Jun;69(6):1945-52
references.pmid: 16505153
references.citation: ChemMedChem. 2007 Jun;2(6):746-67
references.pmid: 17295372
references.citation: Nature. 1995 Mar 2;374(6517):65-7
references.pmid: 7870173
references.citation: Mol Pharmacol. 2002 Feb;61(2):369-78
references.pmid: 11809862
references.citation: Neuropharmacology. 2000 Oct;39(13):2785-91
references.pmid: 11044748
references.citation: Front Biosci. 2008 Jan 01;13:492-504
references.pmid: 17981563
references.citation: J Med Chem. 2001 Nov 22;44(24):4039-41
references.pmid: 11708907
references.citation: J Neurochem. 2002 Aug;82(3):468-81
references.pmid: 12153472
references.citation: J Med Chem. 2002 Oct 10;45(21):4755-61
references.pmid: 12361403
references.citation: Biochim Biophys Acta. 2008 Apr;1778(4):864-71
references.pmid: 18249185
references.citation: J Med Chem. 2005 Mar 24;48(6):1721-4
references.pmid: 15771418
references.citation: Mol Pharmacol. 1994 Apr;45(4):563-9
references.pmid: 8183234
references.citation: J Neurophysiol. 2001 Oct;86(4):1773-82
references.pmid: 11600638
references.citation: Mol Pharmacol. 2003 Dec;64(6):1283-94
references.pmid: 14645658
references.citation: Anal Chem. 2008 Jan 1;80(1):48-54
references.pmid: 18062706
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4734-9
references.pmid: 11274373
references.citation: J Pharmacol Exp Ther. 2002 Sep;302(3):1246-52
references.pmid: 12183686